Pure Global
NCT04906148

Young Adults' Reactions to Low Nicotine Cigarette Advertising

University of Pennsylvania·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Smoking
Drug/Device/Intervention
Advertisement content (explicit vs. implicit)
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Pennsylvania
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
N/A
Start date
May 27, 2021
End date
Dec 15, 2022
Enrollment
340 participants
Primary outcome

Attention,Risk beliefs,Recall,Perceived health risks

Summary

Reducing the nicotine content in combustible cigarettes to non-addictive levels has
 demonstrated promise as a safe and effective public health strategy for decreasing
 tobacco-caused morbidity and mortality. Little data are available, however, assessing how the
 marketing of low nicotine content (LNC) cigarettes could dampen their potential population
 health benefit. This study will examine LNC cigarette advertising content effects on message
 recall, viewing patterns, product perceptions, and use behaviors. Young adults (N = 340; 170
 smokers, 170 non-smokers) will complete a single-session laboratory study using a 2 x 2
 between-subject design to manipulate advertisement messaging accuracy (true vs.
 false/misleading) and content (implicit vs. explicit). Findings may be used to guide public
 health policy decisions related to regulating cigarette nicotine content and marketing.

ICD-10 classifications
Tobacco useExposure to tobacco smokeToxic effect: Tobacco and nicotineMental and behavioural disorders due to use of tobacco : harmful useDrug use
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04906148
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04906148 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Pennsylvania and is currently Recruiting. The study focuses on Smoking. Target enrollment is 340 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.